Avidity Biosciences, INC Schedule 13G passive stakes

RA Capital Management and its affiliates have reported a 0% beneficial ownership stake in Avidity Biosciences, Inc. as of March 31, 2026.

Janus Henderson Group plc has reported a reduction in its beneficial ownership of Avidity Biosciences, Inc. common stock to 4.6% as of December 31, 2025.

T. Rowe Price Associates, Inc. has filed an Amendment No. 8 to Schedule 13G, reporting a 0.1% beneficial ownership in Avidity Biosciences Inc.

Avoro Capital Advisors LLC and Behzad Aghazadeh have disclosed a 5.54% beneficial ownership stake in Avidity Biosciences, Inc. common stock.

Wellington Management Group LLP and its affiliates reported a passive beneficial ownership of 0.48% of Avidity Biosciences, Inc. common stock.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 5.5% in Avidity Biosciences, Inc. common stock.

RA Capital Management and its affiliates reported continued beneficial ownership of 5.9% of Avidity Biosciences, Inc.'s common stock as of September 30, 2025.

T. Rowe Price Associates, Inc. has reported a 7.1% beneficial ownership stake in Avidity Biosciences Inc. common stock as of September 30, 2025.

Janus Henderson Group plc has reported a significant beneficial ownership stake of 10.7% in Avidity Biosciences, Inc. common stock.

FMR LLC and Abigail P. Johnson have filed an amendment to their Schedule 13G, reporting a 2.1% beneficial ownership stake in Avidity Biosciences Inc. as of October 31, 2025.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 15.0% in Avidity Biosciences Inc., holding over 21.5 million shares.

The Vanguard Group has increased its beneficial ownership in Avidity Biosciences Inc. to 9.57% of common stock as of September 30, 2025.

BlackRock, Inc. has reported a 6.4% beneficial ownership stake in Avidity Biosciences, Inc., holding 8,631,771 common shares.

Janus Henderson Group PLC has increased its beneficial ownership in Avidity Biosciences, Inc. to 10.1% of common stock.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 9.5% beneficial ownership stake in Avidity Biosciences, Inc. as of March 31, 2025.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 8.06% in Avidity Biosciences, Inc. as of March 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 13.0% of Avidity Biosciences Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.5% of Avidity Biosciences Inc.'s common stock as of March 31, 2025.

Janus Henderson Group plc has filed a Schedule 13G, reporting a 5.9% beneficial ownership stake in Avidity Biosciences, Inc. as of December 31, 2024.